Abstract 1083
Background
Malignant lymphoma is rarely encountered in health screening program. It is often difficult to recognize it at early stage although the earlier detection would bring the better prognosis like other malignancies.
Methods
Data of screening program with esophagogastroduodenoscopy (EGD) at Ota Memorial Hospital (OMH) in Japan from June 2012 through December 2017 were reviewed and cases of malignant lymphoma detected were analyzed to reveal characteristics.
Results
26886 individuals participated in EGD screening program of OMH in that term. 91 cases of malignant neoplasm were detected and six of them (6.6%) were diagnoses as malignant lymphoma (detection rate 0.02%). They consisted of three gastric and three duodenal lymphomas. None of them had B symptom. Histopathological exam diagnosed all gastric cases as MALT lymphoma locating at middle part of stomach. Their endoscopic findings were as follows; one was scar-like whitish mucosa without stricture, another was whitish mucosa mixed with erythema, and the other was scar-like lesion surrounded nodular and granular mucosae. Although all gastric lymphoma had no eradication history of Helicobacter pylori (Hp) and serum anti-Hp IgG antibody were less than 3 U/ml, one of them had advanced chronic atrophic gastritis. All gastric MALT lymphoma took irradiation therapy. All duodenal lymphomas were diagnosed as follicular lymphoma. One of them located around duodenal papilla was recurrent lesion that had originated in mesenteric lymph nodes and been treated with chemotherapy six years before. Its endoscopic findings were polypoid and granular lesions. Other two duodenal lymphoma were detected at inferior duodenal angle as nodular and granular appearance. The recurrent follicular lymphoma had the second line chemotherapy. Other two cases were treated by irradiation and molecular targeting therapy with rituximab respectively.
Conclusions
Nearly 7% of malignancy detected by EGD screening program of OMH was malignant lymphoma consisting of gastric MALT lymphoma and duodenal follicular lymphoma although it was rarely encountered. Since it shows non-specific endoscopic findings especially at its early stage, mandate biopsy to any suspicious lesion is strongly recommended.
Clinical trial identification
Legal entity responsible for the study
Ota Memorial Hospital.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2595 - Real-Life Utilization of Genomic testing for invasive Breast Cancer patients in Italy and France reduces Chemotherapy Recommendations
Presenter: Sandro Barni
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2343 - Benefit of adjuvant chemotherapy in hormone receptor-positive, HER2-negative, invasive lobular carcinoma of the breast
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2990 - Baseline lymphocyte counts predict distant recurrence in early breast cancer
Presenter: Gun Min Kim
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4532 - A propensity score analysis exploring the impact of the addition of adjuvant chemotherapy (aCT) to hormone therapy (aHT) in a multi-center series of resected luminal early stage pure Invasive Lobular Breast Carcinoma (ILC).
Presenter: Luisa Carbognin
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
2344 - Benefit of Adjuvant Systemic Therapies in HR+ HER2- pT1ab Node-Negative Breast Carcinomas
Presenter: Alexandre De Nonneville
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3525 - Anti-proliferative effect of oral metronomic vinorelbine in PAM50 Luminal/HER2-negative early breast cancer (SOLTI-1501 VENTANA): an open-label, randomized, three-arm, multicenter, window-of-opportunity study
Presenter: Aleix Prat
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3908 - Clinicopathologic significance of androgen receptor expression and discordant receptor status during progression in breast cancer
Presenter: Chan Heun Park
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
4075 - The outcomes of early breast cancers utilizing the Oncotype Dx Recurrence score (RS) instead of Clinico-pathological (CP) factors for prognostic risk assessment: A Single Institution Experience
Presenter: Adhar Alsayed
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
738 - Circulating tumor cells as a prognostic marker in non metastatic breast cancer patients.
Presenter: Summar Elmorshidy
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract
3151 - Molecular subtyping of breast cancer by dedicated breast PET
Presenter: Satoshi Sueoka
Session: Poster display session: Breast cancer - early stage, locally advanced & metastatic, CNS tumours, Developmental therapeutics, Genitourinary tumours - prostate & non-prostate, Palliative care, Psycho-oncology, Public health policy, Sarcoma, Supportive care
Resources:
Abstract